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Background: Improved outcome in tobacco smoking patients with non-small cell
lung cancer (NSCLC) following immunotherapy has previously been reported. How-
ever, little is known regarding this association during first-line immunotherapy in
patients with high PD-L1 expression. In this study we compared clinical outcomes
according to the smoking status of two large multicenter cohorts.
Methods: We compared clinical outcomes according to the smoking status (never smokers
vs. current/former smokers) of two retrospective multicenter cohorts of metastatic NSCLC
patients, treated with first-line pembrolizumab and platinum-based chemotherapy.
Results: A total of 962 NSCLC patients with PD-L1 expression ≥50% who received
first-line pembrolizumab and 462 NSCLC patients who received first-line platinum-
based chemotherapy were included in the study. Never smokers were confirmed to
have a significantly higher risk of disease progression (hazard ratio [HR] = 1.49
[95% CI: 1.15–1.92], p = 0.0022) and death (HR = 1.38 [95% CI: 1.02–1.87],
p = 0.0348) within the pembrolizumab cohort. On the contrary, a nonsignificant
trend towards a reduced risk of disease progression (HR = 0.74 [95% CI: 0.52–1.05],
p = 0.1003) and death (HR = 0.67 [95% CI: 0.45–1.01], p = 0.0593) were reported
for never smokers within the chemotherapy cohort. After a random case–control
matching, 424 patients from both cohorts were paired. Within the matched
pembrolizumab cohort, never smokers had a significantly shorter progression-free
survival (PFS) (HR = 1.68 [95% CI: 1.17–2.40], p = 0.0045) and a nonsignificant
trend towards a shortened overall survival (OS) (HR = 1.32 [95% CI: 0.84–2.07],
p = 0.2205). On the contrary, never smokers had a significantly longer PFS
(HR = 0.68 [95% CI: 0.49–0.95], p = 0.0255) and OS (HR = 0.66 [95% CI: 0.45–
0.97], p = 0,0356) compared to current/former smoker patients within the matched
chemotherapy cohort. On pooled multivariable analysis, the interaction term
between smoking status and treatment modality was concordantly statistically signif-
icant with respect to ORR (p = 0.0074), PFS (p = 0.0001) and OS (p = 0.0020), con-
firming the significantly different impact of smoking status across the two cohorts.
Conclusions: Among metastatic NSCLC patients with PD-L1 expression ≥50% receiv-
ing first-line pembrolizumab, current/former smokers experienced improved PFS
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and OS. On the contrary, worse outcomes were reported among current/former
smokers receiving first-line chemotherapy.
K E YWORD S
immunotherapy, non-small cell lung cancer, pembrolizumab, smoking, tobacco
INTRODUCTION
Programmed death 1 (PD-1) checkpoint inhibitors have
become the backbone of the treatment algorithm of non-
oncogene addicted non-small cell lung cancer (NSCLC)
patients.1 Tobacco use is known to be the main risk factor
for lung cancer development and is related to a high all-
cause morbidity and mortality overall.2 Nevertheless,
smoking of tobacco has been associated with improved out-
comes in NSCLC patients receiving checkpoint inhibitors
across different lines and regardless of programmed death-
ligand 1 (PD-L1) tumor expression.3 Intriguingly, a meta-
analysis has also suggested that checkpoint inhibitors
significantly improve survival over chemotherapy in smoker
patients only.4
We recently published a large (1016 patients) real-world
multicenter study of patients with metastatic NSCLC with PD-
L1 expression ≥50% who received first-line single agent
pembrolizumab at 34 European institutions, aimed at investi-
gating the clinicopathological correlates of efficacy.5,6 Multivar-
iable analysis determined that former smokers (but not current
smokers) experienced significantly prolonged progression-free
survival (PFS) and overall-survival (OS) compared to never
smokers.5 We subsequently gathered a cohort of metastatic
NSCLC patient treated with first-line platinum-based doublet
chemotherapy for the external validation of the role of BMI in
the same study population.7
In order to further assess the role of the baseline
smoking status during first-line single agent immunotherapy
in NSCLC patients with high PD-L1 tumor expression, we
compared the clinical outcomes analyses according to the
smoking status between the above mentioned two cohorts.
METHODS
Study design
We compared the clinical outcomes analyses according to
the smoking status (never vs. current/former smokers) of
two real-world retrospective multicenter cohorts: a cohort of
metastatic NSCLC patients with PD-L1 expression ≥50%,
consecutively treated with first-line pembrolizumab mon-
otherapy, from January 2017 to October 2019, at 34 institu-
tions (Supplementary file 1), and a cohort of metastatic
epidermal growth factor receptor (EGFR) wild-type NSCLC
patients treated with platinum-based doublet chemotherapy
in clinical practice from January 2013 to January 2020, at
10 institutions among the abovementioned.5–7 The mea-
sured clinical outcomes were objective response rate (ORR),
PFS and OS. Methods regarding clinical outcomes estima-
tion in the two cohorts have been previously reported.5–7
A fixed multivariable regression model was used to esti-
mate clinical outcomes (ORR, PFS and OS) according to the
smoking status (current/former smokers vs. never smokers)
in both pembrolizumab and chemotherapy cohorts.8–10 The
key covariates were: age (<70 vs. ≥70 years old),11 gender
(male vs. female), Eastern Cooperative Oncology Group–
Performance Status (ECOG-PS) (0–1 vs. ≥ 2), central ner-
vous system (CNS) metastases (yes vs. no), bone metastases
(yes vs. no) and liver metastases (yes vs. no).
Considering the different sample size, a random case–
control matching was also performed to better compare the
results across the cohorts. All the cases from the chemother-
apy cohort and controls from the pembrolizumab cohort
were randomly paired on the basis of the smoking status
(current/former smokers vs. never smokers) and those char-
acteristics which were significantly unbalanced between the
cohorts: ECOG-PS (0–1 vs. 2), age (< 70 vs. ≥ 70 years old),
and baseline BMI according to the World Health Organiza-
tion categories (underweight, BMI < 18.5; normal-weight,
18.5 ≤ BMI ≤24.9; overweight, 25 ≤ BMI ≤29.9; obese,
BMI ≥30).7
Lastly, to take into account the potential role of all base-
line characteristics, we performed a pooled analysis, using a
multivariable regression model (inclusive of the previously
selected covariates plus primary tumor histology [squamous
vs. nonsquamous] and baseline BMI) including the interac-
tion term between the smoking status and the treatment
modality (pembrolizumab vs. chemotherapy), used as
covariates.
All patients provided their written, informed consent to
treatment with immunotherapy. The procedures followed
were in accordance with the precepts of Good Clinical Prac-
tice and the declaration of Helsinki. The study was approved
by the respective local ethical committees on human experi-
mentation of each institution, after previous approval by the
coordinating center (Comitato Etico per le provice di
L’Aquila e Teramo, verbale N.15 del 28 Novembre 2019).
Median PFS and median OS were evaluated using the
Kaplan–Meier method. Median period of follow-up was cal-
culated according to the reverse Kaplan–Meier method. χ2
test was used for the univariable analysis of ORR, logistic
regression was used for the fixed multivariable analyses of
ORR. Cox proportional hazards regression was used for the
univariable analysis of PFS and OS and for the fixed multi-
variable analyses. The alpha level for all analyses was set to
p < 0.05. Adjusted hazard ratios (HRs) and adjusted odds
ratios (ORs) with 95% confidence intervals (CIs) were calcu-
lated. Forest plot graphs were used to compare HRs between
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the pembrolizumab and chemotherapy cohorts. After the
random case–control matching, clinical outcomes of the two
cohort were compared with univariable analyses. Consider-
ing the sample size of the pembrolizumab cohort (more than
twice the chemotherapy cohort) a caliper width of <1 for the
standard deviation was used for the random case–control
matching.12 All statistical analyses were performed using
MedCalc Statistical Software version 18.11.3 (MedCalc Soft-
ware bvba, Ostend, Belgium; http://www.medcalc.org; 2019).
RESULTS
A total of 962 patients and 426 patients were included in the
pembrolizumab and chemotherapy cohorts, respectively.
Patient characteristics of the two cohorts have already been
previously reported,7 a summary of which is available in
Table S2. A total of 864 patients (89.8%) and 378 patients
(88.7%) were former/current smokers in the pembrolizumab
and chemotherapy cohorts, respectively, and 249 patients
(58.5%) within the chemotherapy cohort had received a fur-
ther treatment with either PD-1 or PD-L1 checkpoint inhib-
itors at the data cutoff.
Table 1 summarizes the univariable analysis of ORR, PFS
and OS. Never smokers had a significantly lower ORR
(p = 0.0367), significantly shorter PFS (HR = 1.74 [95% CI:
1.36–2.23], p < 0.0001) (Figure 1(a)) and OS (HR = 1.59
[95% CI: 1.19–2.13], p = 0.0015) (Figure 1(b)) compared to
former/current smokers within the pembrolizumab cohort.
In the chemotherapy cohort the smoking status was not sig-
nificantly related to the ORR (p = 0.0919), whilst significantly
longer PFS (HR = 0.70 [95% CI: 0.51–0.96], p = 0.0296) and
OS (HR = 0.66 [95% CI: 0.45–0.96], p = 0.0339) were
reported for never smokers.
Table 2 summarizes the multivariable analysis of ORR.
The smoking status was not confirmed to be associated with
ORR in both the pembrolizumab (OR = 0.66 [95% CI: 0.40–
1.09], p = 0.1070), and chemotherapy (OR = 1.83 [95% CI:
0.94–3.70], p = 0.0751) cohorts. Table 3 summarizes the
multivariable analysis of PFS. Never smokers were con-
firmed to have a significantly shorter PFS compared to cur-
rent/former smokers in the pembrolizumab cohort
(HR = 1.49 [95% CI: 1.15–1.92], p = 0.0022). On the other
hand, the opposite association was not confirmed within the
chemotherapy cohort (HR = 0.74 [95% CI: 0.52–1.05],
p = 0.1003) (Figure 2). Similarly, never smokers were con-
firmed to have a significantly shorter OS compared to cur-
rent/former smokers in the pembrolizumab cohort
(HR = 1.38 [95% CI: 1.02–1.87], p = 0.0348), while a nonsig-
nificant trend of a prolonged OS was reported for never
smokers within the chemotherapy cohort (HR = 0.67 [95%
CI: 0.45–1.01], p = 0.0593) (Table 4) (Figure 2).
After the case–control random matching, 424 patients
from the pembrolizumab and chemotherapy cohorts were
perfectly paired, with no statistically significant differences
between the characteristics of matched subjects; 378 (89.2%)
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matched cohorts. In the matched pembrolizumab cohort,
the ORR for current/former smokers and never smokers was
33.2% (95% CI: 27.5–39.8) and 30.9% (95% CI: 16.5–52.9)
(p = 0.7658), respectively; among the matched chemother-
apy cohort the ORR for current/former smokers and never
smokers was 42.4% (95% CI: 36.0–49.5) and 55.6% (95% CI:
35.9–82.0) (p = 0.0923), respectively. Never smokers had a
significantly shorter PFS (HR = 1.68 [95% CI: 1.17–2.40],
p = 0.0045) (Figure 3a) and a nonsignificant trend towards a
shortened OS (HR = 1.32 [95% CI: 0.84–2.07], p = 0.2205)
within the matched pembrolizumab cohort (Figure 3b). On
the contrary, never smokers had a significantly longer PFS
(HR = 0.68 [95% CI: 0.49–0.95], p = 0.0255) (Figure 3c) and
OS (HR = 0.66 [95% CI: 0.45–0.97], p = 0,0356) (Figure 3d)
I’ compared to current/former smoker patients within the
matched chemotherapy cohort.
F I G U R E 1 Kaplan–Meier survival curves according to smoking status. Pembrolizumab cohort (a) progression-free survival (PFS); and (b) overall
survival (OS); chemotherapy cohort (c) PFS and (d) OS. See Table 1 for survival estimations
F I G U R E 2 Forest plot graph
for adjusted hazard ratios (aHRs)
for disease progression (progression-
free survival [PFS]) and death
(overall survival [OS]) according to
smoking status
CORTELLINI ET AL. 5
F I G U R E 3 Kaplan–Meier survival curves according to smoking status within the randomly matched cohorts; Pembrolizumab cohort PFS. (a) Never
smokers 4.7 months (95% CI: 2.8–6.9; 35 progression events), current/former smokers 8.0 months (95% CI: 8.9–10.8; 217 progression events) (p = 0.0045).
OS. (b) Never smokers 12.7 months (95% CI: 7.9–15.0; 24 censored patients), current/former smokers 18.6 months (95% CI:15.2–27.4; 227 censored patients)
(p = 0.2205); PFS. (c) Never smokers 7.4 months (95% CI: 5.1–10.8; 41 progression events), current/former smokers 6.0 months (95% CI: 5.6–6.4; 344
progression events) (p = 0.0255). OS. (d) Never smokers 20.1 months (95% CI: 11.6–31.8; 16 censored patients), current/former smokers 15.8 months (95%
CI: 13.2–18.4; 119 censored patients) (p = 0.0255). PFS, progression-free survival; OS, overall survival





Variable (comparator) Coefficient Standard error OR (95% CI); p-value Coefficient Standard error OR (95% CI); p-value
Smoking status
(never vs. current/former)
0.411 0.255 0.66 (0.40–1.09); p = 0.1070 −0.606 0.340 1.83 (0.94–3.57); p = 0.0751
Gender
(male vs. female)
0.006 0.155 0.99 (0.73–1.34); p = 0.9651 0.131 0.229 0.88 (0.56–1.37); p = 0.5672
Age
(elderly vs. non-elderly)
0.034 0.145 0.96 (0.72–1.28); p = 0.8108 0.547 0.210 0.58 (0.38–0.87); p = 0.0093
CNS metastases
(yes vs. no)
0.031 0.188 0.97 (0.67–1.40); p = 0.8665 −0.015 0.279 1.02 (0.58–1.75); p = 0.9545
Bone metastases
(yes vs. no)
0.662 0.161 0.51 (0.37–0.71); p < 0.0001 0.683 0.244 0.50 (0.31–0.81); p = 0.0050
Liver metastases
(yes vs. no)
0.364 0.211 0.69 (0.45–1.05); p = 0.0853 0.593 0.317 0.55 (0.29–1.03); p = 0.0616
ECOG PS ≥2 vs. (0–1) 0.942 0.216 0.39 (0.26–0.59); p = 0.0038 0.176 0.405 0.83 (0.37–1.85); p = 0.6632
Abbreviations: CNS, central nervous system; ECOG, Eastern Cooperative Oncology Group; OR, odds ratio.
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Variable (comparator) HR (95% CI); p-value HR (95% CI); p-value
Smoking status (never vs. current/former) 1.49 (1.15–1.92); p = 0.0022 0.74 (0.52–1.05); p = 0.1003
Gender (male vs female) 0.99 (0.83–1.19); p = 0.9574 1.21 (0.96–1.54); p = 0.1018
Age (elderly vs. nonelderly) 1.07 (0.90–1.27); p = 0.4282 1.17 (0.95–1.44); p = 0.1345
CNS metastases (yes vs. no) 1.21 (0.98–1.50); p = 0.0733 1.08 (0.81–1.44); p = 0.5611
Bone metastases (yes vs. no) 1.60 (1.33–1.91); p < 0.0001 1.32 (1.05–1.65); p = 0.0160
Liver metastases (yes vs. no) 1.75 (1.41–2.16); p < 0.0001 1.37 (1.02–1.83); p = 0.0338
ECOG PS ≥2 vs (0–1) 2.42 (1.98–2.94); p < 0.0001 2.16 (1.46–3.21); p = 0.0001
Abbreviations: CNS, central nervous system; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio.
TA B L E 4 Summary of the overall survival (OS) multivariable analysis in the pembrolizumab and chemotherapy cohorts
Pembrolizumab cohort Overall survival Chemotherapy cohortOverall survival
Variable (comparator) HR (95% CI); p-value HR (95% CI); p-value
Smoking status (never vs. current/former) 1.38 (1.02–1.87); p = 0.0348 0.67 (0.45–1.01); p = 0.0593
Gender (male vs. female) 1.11 (0.89–1.39); p = 0.3131 1.05 (0.80–1.39); p = 0.6918
Age (elderly vs. nonelderly 1.10 (0.90–1.35); p = 0.3298 1.22 (0.96–1.55); p = 0.1005
CNS metastases (yes vs. no) 1.15 (0.89–1.48); p = 0.2743 1.27 (0.92–1.76); p = 0.1396
Bone metastases (yes vs. no) 1.68 (1.36–2.07); p < 0.0001 1.38 (1.06–1.80); p = 0.0144
Liver metastases (yes vs. no) 1.69 (1.32–2.16); p < 0.0001 1.23 (0.86–1.75); p = 0.2427
ECOG PS ≥2 vs (0–1) 2.95 (2.36–6.69); p < 0.0001 2.44 (1.65–3.63); p < 0.0001
Abbreviations: CNS, central nervous system; ECOG, Eastern Cooperative Oncology Group.
TA B L E 5 Pooled multivariable analysis including the interaction term between treatment modality and smoking status
Objective response rate Progression-free survival Overall survival
Variable (comparator) OR (95% CI); p–value HR (95% CI); p–value HR (95% CI); p-value
Treatment modality (chemotherapy vs.
pembrolizumab)
0.79 (0.61–1.03); p = 0.0799 1.93 (1.67–2.23); p < 0.0001 1.27 (1.07–1.51); p = 0.0055
Smoking status (never vs. current/former) 0.68 (0.41–1.12); p = 0.1236 1.71 (1.32–2.25); p < 0.0001 1.51 (1.12–2.04); p = 0.0060
Interaction smoking status*treatment modality p = 0.0074 p = 0.0001 p = 0.0020
ECOG PS (≥ 2 vs. 0–1) 0.46 (0.31–0.67); p = 0.0001 2.39 (2.01–2.85); p < 0.0001 2.88 (2.37–3.49); p < 0.0001
Gender (male vs. female) 0.98 (0.75–1.26); p = 0.8317 1.04 (0.90–1.21); p = 0.5111 1.12 (0.94–1.33); p = 0.1966
Age (elderly vs. nonelderly) 0.83 (0.66–1.06); p = 0.1295 1.08 (0.94–1.23) p = 0.2531 1.15 (0.99–1.35); p = 0.0650
CNS metastases (yes vs. no) 0.99 (0.72–1.35); p = 0.9193 1.17 (0.99–1.39); p = 0.0611 1.19 (0.97–1.45); p = 0.0861
Liver metastases (yes vs. no) 0.64 (0.45–0.91); p = 0.0124 1.63 (1.37–1.93); p < 0.0001 1.51 (1.24–1.85); p < 0.0001
Bone metastases (yes vs. no) 0.51 (0.38–0.66); p < 0.0001 1.53 (1.33–1.77); p < 0.0001 1.57 (1.33–1.85); p < 0.0001
BMI
Normal weight (comparator)
Underweight 0.53 (0.27–1.01); p = 0.0520 1.26 (0.91–1.74); p = 0.1619 0.97 (0.65–1.44); p = 0.9062
Overweight 0.78 (0.59–1.02); p = 0.0612 0.98 (0.85–1.14); p = 0.8728 0.91 (0.76–1.08); p = 0.3176
Obese 1.41 (0.98–2.04); p = 0.0665 0.81 (0.66–1.01); p = 0.0620 0.89 (0.69–1.14); p = 0.3776
Histology
Nonsquamous vs. squamous 1.07 (0.81–1.42); p = 0.6202 0.85 (0.73–0.99); p = 0.0483 0.94 (0.78–1.14); p = 0.5765
Abbreviations: CNS, central nervous system; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio.
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Table 5 summarizes the multivariable regression ana-
lyses from the pooled population for ORR, PFS and OS
including all the baseline patient characteristics. At the
pooled analysis, the interaction term between the smoking
status and treatment modality was concordantly statistically
significant with respect to ORR (p = 0.0074), PFS
(p = 0.0001) and OS (p = 0.0020), confirming the signifi-
cantly different impact of smoking status across the two
cohorts.
DISCUSSION
The primary aim of this analysis was to further evaluate the
opposite role of the smoking status according to the first-
line treatment modality in NSCLC patients. The fixed multi-
variable analyses confirmed that never smokers had signifi-
cantly shortened PFS and OS compared to current/former
smokers among NSCLC patients with PD-L1 expression
≥50% receiving first-line pembrolizumab. On the contrary, a
trend towards prolonged PFS and OS was reported for never
smoker patients receiving first-line platinum-based chemo-
therapy. Of note, never smokers achieved a prolonged OS
within the chemotherapy cohort, despite 58.5% of patients
receiving PD-1/PD-L1 checkpoint inhibitors as a later line
of treatment. Even though a significantly lower ORR was
reported for never smokers on the univariable analysis in
the pembrolizumab cohort, no further significant associa-
tions between smoking habit and ORR were found.
The random case–control matching strengthened our
findings with regard to PFS. Never smokers had a signifi-
cantly shorter PFS and a trend towards a shortened OS
within the matched pembrolizumab cohort. Conversely, sig-
nificantly longer PFS and OS were reported for never
smokers, compared to current/former smokers, within the
matched chemotherapy cohort. Finally, the concordantly
statistically significant interaction term between the treat-
ment modality (pembrolizumab vs. chemotherapy) and
smoking status with respect to ORR, PFS and OS at the
pooled analysis, further confirmed the differential role of the
smoking status between the cohorts, regardless of any other
baseline characteristics.
The tumor mutational burden (TMB) has been already
proposed as an agnostic predictive biomarker for PD-1
checkpoint inhibitors across different malignancies, even
though its applicability in the real-life context is still
controversial.13–15 Nevertheless, the TMB could have its own
complementary and independent role from PD-L1 immuno-
histochemical evaluation.16,17 It has been reported that
smoking-induced carcinogenesis is associated with a higher
TMB,18 to such an extent that it has been assumed that
smoking-related lung cancer is more likely to be immuno-
genic.19 Interestingly, Rizvi et al. reported that a smoking-
associated genomic signature, characterized by high fre-
quency of transversion, was significantly associated to
improved ORR and PFS among 34 advanced NSCLC patients
treated with pembrolizumab, whilst the self-reported
smoking history did not significantly predict the clinical out-
come within the same population.20 Recently, Gainor et al.
reported that among NSCLC patients with PD-L1 expression
≥50% receiving first-line single agent pembrolizumab, heavy
smokers experienced numerically better outcomes compared
to never/light smokers.21 Moreover, they confirmed that the
TMB was higher within heavy smoker patients, compared to
light/never smokers, while no significant differences were
found between light and never smokers.21 In addition, we
have to consider that tobacco smoking exposure has been
also associated with increasing in vivo and in vitro
intratumoral PD-L1 expression.22 Concordantly, we previ-
ously reported a significant trend towards an increased PD-
L1 expression according to the smoking status (never, former
and current smokers) within our study population.6
In the context of single-agent pembrolizumab, current/for-
mer smokers have already been confirmed to experience
improved ORR and prolonged survival within the phase I Key-
note 001 trial population.23,24 Similarly, the subgroup analysis
of the Keynote 024 trial revealed that the survival benefit for
single agent pembrolizumab over chemotherapy in NSCLC
patients with high PD-L1 expression was greater for former
smokers, compared to current and never smokers.25 On the
contrary, in the Keynote 189 trial, the subgroup analysis
showed no significant differences according to smoking status.
However, the survival benefit for the experimental arm (che-
motherapy/pembrolizumab) over the control arm (chemother-
apy/placebo) was greater for never smokers (HR for death
0.23), compared to current/former smokers (HR for death
0.54), appearing that the addition of chemotherapy had flat-
tened the smoking-related effects on immunotherapy.26
Intriguingly, the TMB was not significantly associated with
efficacy in both arms of the same trial population.27
From this perspective, considering the smoking status as
an easily available surrogate for the underlying TMB, it
might be used to assist clinicians in the decision-making
process for first-line treatment. With that in mind, a combi-
national approach, rather than single agent pembrolizumab,
might be taken into consideration with greater solicitude in
never smoker patients with high PD-L1 expression, com-
pared to former/current smokers.
Certainly, we are a long way from minimizing the strong
negative role of smoking overall. In fact, in this study popu-
lation we already confirmed that former smokers experi-
enced the best outcome, compared to current and never
smokers,6 suggesting the presence of an underlying global/
functional benefit from smoking cessation, without
impairing the TMB-gain related to the smoking habit.
Several study limitations have to be acknowledged
beyond the retrospective design and consequent selection
biases. The biggest flaw in the study was the lack of informa-
tion regarding quantification of the smoking status. For a
proper estimation of its effect, it should have been classified
in a more quantitative way (e.g., pack per year), as has
already been determined in other studies.21 Moreover, we
were not able to separately assess former/current smokers
within the chemotherapy cohort because this analysis was
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not preplanned. Additionally, the chemotherapy cohort was
not powered to detect significant findings according to
smoking categories and being a historic cohort we did not
have data regarding PD-L1 expression. However, consider-
ing the real-world prevalence of PD-L1 expression in
NSCLC, we assumed that one third of the patients in the
chemotherapy cohort had a PD-L1 expression ≥50%.28 TMB
is not routinely assessed in clinical practice in Europe, and
therefore we were unable to perform a correlation analyses.
Moreover, we should also consider the true incidence of
oncogene addiction in NSCLC beyond EGFR, ALK and
ROS-1, which are regularly evaluated as it is known that
oncogene addiction is inversely related with smoking status
and immunotherapy efficacy.29 Additional limitations
include the lack of available data regarding comorbidities
which might have been affected by smoking habit.
In conclusion, our study confirmed that current/former
smoker NSCLC patients with PD-L1 expression ≥50%
receiving first-line single agent pembrolizumab experienced
improved PFS and OS compared to never smokers, whilst
the opposite trend was found within NSCLC patients treated
with first-line platinum-based chemotherapy. The random
case–control matching and the pooled analysis further
strengthened our results on the opposite role of smoking
during immunotherapy and chemotherapy. The putative
predictive role of the smoking status in this setting needs to
be assessed in prospective controlled trials.
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